The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer
暂无分享,去创建一个
Diego Romero | J. Roa | U. Kronberg | Karen Dubois-Camacho | R. Quera | D. Simian | Maripaz Martínez | G. Landskron | María-Julieta González | Juan Carlos Roa | Glauben Landskron | María-Julieta González | Marjorie De la Fuente López | Daniela Parada | Karen Dubois-Camacho | Daniela Simian | Maripaz Martinez | Isidora Chahuán | Rocío Gutiérrez | Francisco Lopez-K | Karin Alvarez | Udo Kronberg | Sebastian López | Antonella Sanguinetti | Natalia Moreno | Mario Abedrapo | Rodrigo Quera | Marcela A Hermoso-R | Mario A. Abedrapo | K. Álvarez | Marjorie De la Fuente López | Diego Romero | D. Parada | Isidora Chahuán | Rocío Gutiérrez | Francisco Lopez-K | Sebastian López | A. Sanguinetti | Natalia Moreno
[1] F. M. Gabhann,et al. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer , 2007, British Journal of Cancer.
[2] P. Allavena,et al. Expression of chemokines and chemokine receptors in human colon cancer. , 2009, Methods in enzymology.
[3] N. Mukaida,et al. Chemokines in Cancer Development and Progression and Their Potential as Targeting Molecules for Cancer Treatment , 2014, Mediators of inflammation.
[4] J. Pober,et al. Tumour necrosis factor and cancer , 2013, The Journal of pathology.
[5] T. Langmann,et al. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro‐ and antiinflammatory stimuli , 2000, Journal of leukocyte biology.
[6] A. Sica,et al. Macrophage plasticity and polarization in tissue repair and remodelling , 2013, The Journal of pathology.
[7] J. Carethers,et al. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. , 2015, Gastroenterology.
[8] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[9] Silvano Sozzani,et al. The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.
[10] E. Kuipers,et al. Colorectal cancer screening: a global overview of existing programmes , 2015, Gut.
[11] S. Gordon,et al. Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.
[12] Ruo-Pan Huang,et al. Tumor-induced perturbations of cytokines and immune cell networks. , 2014, Biochimica et biophysica acta.
[13] H. Nielsen,et al. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma , 2002, British Journal of Cancer.
[14] A. Mantovani,et al. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.
[15] U. Hopt,et al. Chemokines in human colorectal carcinoma. , 2005, Anticancer research.
[16] Ying Liu,et al. Radioactive 125I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathway , 2015, BMC Cancer.
[17] A. Mantovani,et al. Tumor-Associated Macrophages as a Paradigm of Macrophage Plasticity, Diversity, and Polarization: Lessons and Open Questions , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[18] Z. Halpern,et al. Tumor macrophages are pivotal constructors of tumor collagenous matrix , 2016, The Journal of experimental medicine.
[19] D. McMillan,et al. Cancer and systemic inflammation: treat the tumour and treat the host , 2014, British Journal of Cancer.
[20] D. Wågsäter,et al. Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer , 2017, World journal of gastroenterology.
[21] Charles James Kirkpatrick,et al. Histopathological features predict metastatic potential in locally advanced colon carcinomas , 2015, BMC Cancer.
[22] F. López-Köstner,et al. Increasing crude and adjusted mortality rates for colorectal cancer in a developing South American country , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[23] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[24] P. Allavena,et al. Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer , 2016, PloS one.
[25] Yuan Zhang,et al. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. , 2013, European journal of cancer.
[26] Hideki Ueno,et al. Histologic Categorization of Desmoplastic Reaction: Its Relevance to the Colorectal Cancer Microenvironment and Prognosis , 2015, Annals of Surgical Oncology.
[27] H. Ueno,et al. Prognostic impact of histological categorisation of epithelial–mesenchymal transition in colorectal cancer , 2014, British Journal of Cancer.
[28] M. Provencio,et al. Cancer‐associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients , 2013, Cancer science.
[29] M. Kinouchi,et al. Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients. , 2012, Hepato-gastroenterology.
[30] A. B. Lyons,et al. Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania major , 2018, Front. Immunol..
[31] A. Darzi,et al. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer , 2007, Clinical & Experimental Metastasis.
[32] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[33] P. Gibbs,et al. Systemic Inflammation - Impact on Tumor Biology and Outcomes in Colorectal Cancer , 2015 .
[34] B. Pitard,et al. CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma , 2011, PloS one.
[35] S. Shi,et al. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages , 2015, BMC Cancer.
[36] M. Barbosa,et al. Decellularized human colorectal cancer matrices polarize macrophages towards an anti-inflammatory phenotype promoting cancer cell invasion via CCL18. , 2017, Biomaterials.
[37] Klaus Pfeffer,et al. Biological functions of tumor necrosis factor cytokines and their receptors. , 2003, Cytokine & growth factor reviews.
[38] R. Bloigu,et al. The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer , 2016, International journal of cancer.
[39] P. Allavena,et al. The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination , 2016, The Journal of Immunology.
[40] J. Goodwin,et al. Plasma cytokine levels in a population-based study: relation to age and ethnicity. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.
[41] S. Gordon,et al. The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.
[42] Matthew J. Craig,et al. CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization* , 2009, The Journal of Biological Chemistry.
[43] M. De la Fuente,et al. Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.
[44] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.
[45] Marco Erreni,et al. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer , 2011, Cancer Microenvironment.
[46] J. Väyrynen,et al. Detailed analysis of inflammatory cell infiltration in colorectal cancer , 2013, British Journal of Cancer.
[47] G. de Toma,et al. Desmoplasia Influenced Recurrence of Disease and Mortality in Stage III Colorectal Cancer within Five Years after Surgery and Adjuvant Therapy , 2017, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[48] M. Raes,et al. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide , 2015, BMC Cancer.
[49] E. Cukierman,et al. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. , 2015, Trends in biotechnology.
[50] I. Talbot,et al. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer , 2004, Gut.
[51] C. Appleyard,et al. Colonic macrophage polarization in homeostasis, inflammation, and cancer. , 2016, American journal of physiology. Gastrointestinal and liver physiology.
[52] A. Zlotnik,et al. Chemokines: a new classification system and their role in immunity. , 2000, Immunity.
[53] T. Vlaykova,et al. The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients’ survival , 2013, Journal of Molecular Histology.
[54] Noam Brown,et al. The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.
[55] N. Minagawa,et al. Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. , 2002, Anticancer research.
[56] Yukio Fujiwara,et al. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. , 2016, Advanced drug delivery reviews.
[57] K. Matsushima,et al. Crucial involvement of the CCL3‐CCR5 axis‐mediated fibroblast accumulation in colitis‐associated carcinogenesis in mice , 2014, International journal of cancer.
[58] Soo-Ki Kim,et al. Association of serum and intratumoral cytokine profiles with tumor stage and neutrophil lymphocyte ratio in colorectal cancer. , 2014, Anticancer research.
[59] B. Kołodziej,et al. Protein Expression and Genetic Variation of IL32 and Association with Colorectal Cancer in Swedish Patients. , 2018, Anticancer Research.
[60] E. Giannoni,et al. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression , 2014, Oncogene.
[61] M. Roussel,et al. TNF Counterbalances the Emergence of M2 Tumor Macrophages. , 2015, Cell reports.
[62] M. Koch,et al. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. , 2016, Cancer cell.